Nevirapine


Concise Prescribing Info
Indications/Uses
HIV infection.
Dosage/Direction for Use
Adult : PO Combined w/ other antiretrovirals: 200 mg once daily for the 1st 14 days; up to 200 mg twice daily if rash does not develop. Re-introduce at a lower dose for the 1st 14 days if treatment is interrupted for >7 days.
Dosage Details
Oral
HIV infection
Adult: Combined with other antiretrovirals: 200 mg once daily for the first 14 days; increase to 200 mg bid if rash does not develop. Interrupting the treatment for >7 days necessitate reintroduction at a lower dose for the first 14 days.
Child: Combined with other antiretrovirals: 2 mth to 8 yr: 4 mg/kg once daily for the first 14 days; increase to 7 mg/kg bid if no rash is present. 8-16 yr: 4 mg/kg once daily for 14 days followed by 4 mg/kg bid. Max: 400 mg daily. Interrupting the treatment for >7 days necessitate reintroduction at a lower dose for the first 14 days.
Renal Impairment
Haemodialysis: A further 200-mg dose is recommended after dialysis.
Administration
May be taken with or without food.
Contraindications
Hypersensitivity. Lactation. Severe hepatic impairment.
Special Precautions
Pregnancy. Interrupt treatment if severe hepatotoxicity or life-threatening skin reactions develop. Renal or hepatic insufficiency. Monitor liver function periodically.
Adverse Reactions
Skin rash, nausea, vomiting, headache, abnormal LFT, fatigue, diarrhoea, abdominal pain.
Potentially Fatal: Severe and life-threatening hepatotoxic and skin reactions.
Overdosage
Symptoms: Oedema, erythema nodosum, fatigue, fever, headache, insomnia, nausea, pulmonary infiltrates, rash, vertigo, wt loss. Management: No known antidote.
Drug Interactions
Mutually increased levels effects when used with drugs extensively metabolised by CYP3A. Reduced levels/effects of methadone.
Food Interaction
Reduced serum levels with St John's wort.
Action
Description: Nevirapine is a non-nucleoside reverse transcriptase inhibitor that acts against HIV-1. It binds directly to reverse transcriptase and thereby blocks the RNA-dependent and DNA-dependent DNA polymerase activities by disrupting the enzyme's catalytic site.
Pharmacokinetics:
Absorption: Readily absorbed from the GI tract; peak plasma concentrations after 4 hr (oral).
Distribution: Crosses the placenta; enters breast milk. Protein-binding: Approx 60%.
Metabolism: Hepatic by microsomal enzymes.
Excretion: Via urine (as glucuronide conjugates of the hydroxylated metabolites).
Storage
Store at 15-30°C (59-86°F).
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Nevirapine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
  • Nivepin 200
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in